On March 26, 2021, the PTAB issued its Final Written Decision in Mylan Pharmaceuticals, Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2019-01657, which involved Sanofi’s Patent RE47,614 (“’614 patent”) relating to its LANTUS (insulin glargine) product. The PTAB ruled in favor of Mylan and held all 18 claims invalid for obviousness in view of a combination of three references. The ’614 patent is a reissue of U.S. Patent No. 9,132,237.  The ’614 patent is directed to the mechanics of a drug delivery pen device for dispensing dosed drug from a cartridge. As we previously reported [Mylan Files Two Petitions for IPR of Sanofi’s Insulin Glargine Patents – Big Molecule Watch], the parties have been in active court litigation and IPR challenges relating to Sanofi’s patent portfolio for LANTUS since early as 2017.